ClinicalTrials.gg
RecruitingNCT06884280PALaDINUpdated May 6, 2026

Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study

A Phase 3 interventional study of Monofer (iron isomaltoside 1000) and Ferrous Sulfate in Peritoneal Dialysis, Anaemia and Iron Deficiency, Anaemia, sponsored by Hull University Teaching Hospitals NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Hull University Teaching Hospitals NHS Trust · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 29 studies testing iron isomaltoside 1000 in Anemia — 11 open to participants now, 11 under way, 3 of them phase 3. iron isomaltoside 1000 · Anemia.

Planned enrollment
25th of 29
30 · median 120
Started
2025
with 5 others
Phase 3
9 of 29
3 open now
Primary completion
2027-10
later than 6 of 10 live
Registered
24th of 29
by date
Lead sponsor
1 of 29
Hull University Teaching Hospitals NHS Trust

Among the 29 studies testing iron isomaltoside 1000 in Anemia, this one is the 25th largest by planned enrollment, is one of 6 that started in 2025, is one of 9 in phase 3, reaches primary completion later than 6 of the 10 other live ones, and was the 24th registered.

Anemia

1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.

Browse Anemia studies →

Open to participants now

11 of the 29 studies testing iron isomaltoside 1000 in Anemia are open now, in 6 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing iron isomaltoside 1000 in Anemia, or all of them as a file.
02

Study summary

Chronic kidney disease affects a significant portion of the UK population, with approximately 3.5 million adults diagnosed. At its most severe stage, end-stage kidney disease, individuals require frequent dialysis treatment. One form of dialysis, known as peritoneal dialysis, involves introducing and removing fluid from the abdominal cavity to help filter out toxins from the body.

The kidneys are involved in various hormonal processes, including those responsible for producing red blood cells, making anaemia a common consequence of kidney failure. When designing a clinical trial to evaluate the effectiveness of any treatment, it is essential to determine the number of suitable and willing participants, as well as those who can complete all required tests and measurements. Identifying the most appropriate measurement to assess the impact of intravenous iron (iron injected directly into veins) is crucial to ensure that any observed changes are meaningful to people with CKD and their carers. To address these considerations, the investigators will conduct a pilot feasibility trial.

In this trial, individuals with kidney disease undergoing peritoneal dialysis will be randomly assigned to receive either high-dose or low-dose intravenous iron, or oral iron therapy. Over twelve months, the investigators will monitor their anaemia response, symptoms of kidney disease, quality of life, physical performance (such as the ability to walk for six minutes), and cognitive function. Additionally, the investigators will assess the impact of each intervention on the frequency of blood transfusions, whether those on oral iron require intravenous iron, and any changes in the dosage of erythropoietin-stimulating agents (drugs that increase blood production).

03

Conditions studied

  • Peritoneal Dialysis
  • Anaemia
  • Iron Deficiency, Anaemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females aged ≥18 years.
  • Able to give
  • Serum ferritin \<700ug/L
  • Transferrin saturation level \<40%
  • No intravenous iron for last 4 weeks before randomisation (patients may be pre-identified and included after 4-week )
  • Received maintenance peritoneal dialysis therapy for at least 4 weeks
  • Expected to remain on peritoneal dialysis therapy for duration of study

Exclusion criteria

Exclusion Criteria:

  • Inadequate dialysis deemed by responsible clinician
  • Probability of need for transfusion within 1 week of enrolment
  • On or received a HIF-PHI in the past 4 weeks
  • Anticipated major surgery that the responsible clinician feels will impact response to treatment
  • Haemochromatosis / haemosiderosis or >x3 normal
  • Are deemed to be most suited to best-supportive or end-of-life care at time of screening
  • Women of not using effective means of
  • Have been involved in another medicinal study (CTIMP) within past 4 weeks
  • Known allergy or adverse reaction to oral or intravenous iron preparations
  • CRP >50, TSATs >40%, SF >700 at time of recruitment
  • Active infection, , active Hep B or C
  • Are unable or unwilling to consent to or complete the study procedures
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Oral

    Ferrous Sulphate 200mg once daily (oral)

    Drug: Ferrous Sulfate

  • Experimental
    Reactive Intravenous

    IV Monofer up to every 3 months. Administered if ferritin \<100 ug/L and TSAT \<20%

    Drug: Monofer (iron isomaltoside 1000)

  • Experimental
    Proactive Intravenous

    IV Monofer up to every 3 months. Administered if ferritin \<700 ug/L and TSAT \<40%

    Drug: Monofer (iron isomaltoside 1000)

Interventions

06

What researchers measure

Primary outcomes

  1. Eligibility to consent rate (%)

    This refers to the proportion of participants who are eligible for the study and who provide informed consent to participate. Measuring Eligibility to Consent Eligibility-to-Consent Rate: (Number of eligible participants who consented / Total number of eligible participants) × 100% A low eligibility-to-consent ratio may suggest challenges in participant engagement, while a high ratio indicates good participant willingness to take part.

    Time frame: From enrollment to the end of treatment at 12 months

  2. Recruitment rate (%)

    The recruitment rate refers to the speed at which participants are enrolled into a study over a given time period. Measuring Recruitment Rate Recruitment Rate: (Number of participants enrolled / Time period, e.g., per month) For multi-site studies, it can be adjusted per site: Recruitment Rate per Site: (Total participants enrolled / Number of sites × Time period) A high recruitment rate suggests effective recruitment strategies, while a low rate may highlight recruitment barriers.

    Time frame: From enrollment to the end of treatment at 12 months

  3. Participant retention to 12 month follow-up (%)

    Participant retention refers to the proportion of participants who remain in the study and complete follow-up assessments over time. Measuring Retention Retention Rate at Follow-Up: (Number of participants completing follow-up assessments / Total participants enrolled) × 100% A high retention rate reflects good participant engagement, while a low rate may suggest challenges such as participant burden or study fatigue.

    Time frame: From enrollment to the end of treatment at 12 months

  4. Completion of clinical outcomes at follow-up and patterns of missing data for the study measures (%)

    This refers to the proportion of participants who complete the clinical outcomes measures at follow-up. Measuring Completion of Clinical Outcomes Completion Rate of Clinical Outcomes: (Number of participants with complete clinical outcome data / Total participants expected at follow-up) × 100% This measures how well the study is able to collect necessary data, with a high completion rate indicating effective data collection processes.

    Time frame: From enrollment to the end of treatment at 12 months

  5. Completion of patient symptom questionnaires throughout the study (%)

    This refers to the proportion of scheduled symptom questionnaires that participants complete during the study. It is an important measure of participant engagement and the completeness of patient-reported outcome data. Measuring Completion of Patient Symptom Questionnaires Questionnaire Completion Rate: (Number of completed questionnaires / Total number of expected questionnaires) × 100% A high completion rate indicates good participant involvement and reliable data, while a low rate may suggest that the questionnaires are burdensome, inconvenient, or not seen as valuable by participants.

    Time frame: From enrollment to the end of treatment at 12 months

  6. Treatment adherence (%)

    Treatment adherence refers to how well participants follow the prescribed treatment regimen, whether it is medication, lifestyle changes, or other interventions. Measuring Adherence Adherence Rate: (Number of prescribed doses/sessions completed / Total prescribed doses/sessions) × 100% A high adherence rate indicates good compliance, while a low rate may indicate barriers such as treatment side effects, participant preference, or complexity of the regimen.

    Time frame: From enrollment to the end of treatment at 12 months

  7. Treatment fidelty (%)

    Treatment fidelity refers to the degree to which the intervention is delivered as per the study protocol, ensuring consistency across all participants and study sites. Measuring Fidelity Fidelity Rate: (Number of intervention components delivered as intended / Total expected intervention components) × 100% A high fidelity rate suggests that the intervention is being delivered consistently as intended, while a low rate may indicate deviations in protocol delivery.

    Time frame: From enrollment to the end of treatment at 12 months

  8. Treatment acceptability (%)

    Treatment acceptability refers to how acceptable participants or healthcare providers find the study intervention, including factors such as ease of use, side effects, and perceived effectiveness. Measuring Acceptability Acceptability Rate: (Number of participants rating treatment as acceptable / Total participants assessed) × 100% Acceptability is often measured through surveys or questionnaires, and a high rate indicates that participants find the treatment tolerable and beneficial. Low acceptability may highlight barriers such as side effects or perceived inefficacy.

    Time frame: From enrollment to the end of treatment at 12 months

Secondary outcomes

  1. Adverse and serious adverse events

    Adverse Events (AEs) An adverse event (AE) is any unwanted or harmful medical occurrence in a participant receiving a study intervention, regardless of whether it is directly related to the intervention. This includes symptoms, abnormal lab findings, or worsening of an existing condition. Measuring AEs Incidence Rate: (Number of participants experiencing at least one AE / Total participants enrolled) × 100% AE Frequency: Total number of AEs / Total participants enrolled Severity Grading: Often classified as mild, moderate, or severe based on clinical criteria (e.g., CTCAE grading system).

    Time frame: From enrollment to the end of treatment at 12 months

  2. Mortality and Major Adverse Cardiovascular Events (MACE)

    Mortality and Major Adverse Cardiovascular Events (MACE) Mortality refers to the number of deaths occurring in the study population. Major Adverse Cardiovascular Events (MACE) typically include cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and heart failure hospitalisation. Measuring Mortality and MACE Mortality Rate: (Number of deaths / Total participants enrolled) × 100% MACE Incidence Rate: (Number of participants experiencing at least one MACE / Total participants enrolled) × 100% Event-Specific Rates: Tracking occurrences of cardiovascular death, myocardial infarction, stroke, and heart failure admissions separately.

    Time frame: From enrollment to the end of treatment at 12 months

  3. Hospital Admissions

    This includes any unplanned or planned hospitalisations occurring during the study period. It is a key measure of disease burden and healthcare utilisation. Measuring Hospital Admissions Hospital Admission Rate: (Number of participants admitted to hospital / Total participants enrolled) × 100% Admission Frequency: Total number of hospital admissions / Total participants enrolled Length of Stay: Average number of days spent in hospital per admission

    Time frame: From enrollment to the end of treatment at 12 months

  4. Drug Reactions

    This includes any adverse reactions or side effects experienced by participants due to study medication. Reactions can range from mild to severe, including life-threatening anaphylaxis or organ toxicity. Measuring Drug Reactions Incidence Rate: (Number of participants experiencing at least one drug reaction / Total participants receiving the drug) × 100% Severity Grading: Categorising reactions as mild, moderate, severe, or life-threatening Causality Assessment: Evaluating whether the reaction is likely related to the study drug

    Time frame: From enrollment to the end of treatment at 12 months

  5. Infections and Peritoneal Dialysis Peritonitis

    This includes any infections occurring during the study, with a specific focus on peritoneal dialysis (PD) peritonitis, a serious complication in PD patients. Measuring Infections and PD Peritonitis Infection Rate: (Number of participants experiencing at least one infection / Total participants enrolled) × 100% PD Peritonitis Rate: Number of peritonitis episodes / Total PD patient-months Pathogen Identification: Categorising infections based on microbiological findings (e.g., Gram-positive, Gram-negative, fungal) Antibiotic Response Rate: (Number of resolved infections with first-line antibiotics / Total treated infections) × 100%

    Time frame: From enrollment to the end of treatment at 12 months

  6. Quality of life (KDQoL-SF)

    Quality of life (QoL) refers to participants' overall well-being, encompassing physical, emotional, and social aspects of life. It is typically measured using validated tools or disease-specific instruments (KDQoL-SF) Measuring Quality of Life QoL Score: (Sum of individual item scores / Total possible score) × 100% Higher scores indicate better quality of life, while lower scores suggest poorer well-being.

    Time frame: From enrollment to the end of treatment at 12 months

  7. Symptom burden (IPOS-Renal, PROMIS Global Health Instrument)

    Symptom burden refers to the overall impact of symptoms on a participant's daily life, including severity, frequency, and the level of distress caused by symptoms. This can include fatigue, pain, nausea, and other symptoms. Measuring Symptom Burden Symptom Burden Score: (Sum of symptom severity scores / Total number of symptoms assessed) × 100% This can be assessed using symptom scales or questionnaires, where a higher score typically represents a higher symptom burden. Changes in symptom burden are tracked over time to evaluate the effect of the intervention.

    Time frame: From enrollment to the end of treatment at 12 months

  8. Physical Function (6-Minute Walk Test)

    The 6-minute walk test (6MWT) is a measure of a participant's physical endurance and functional capacity, assessing how far they can walk in six minutes. It is often used to evaluate patients with chronic conditions, including those with kidney disease. Measuring Physical Function (6-Minute Walk Test) Distance Walked: Total distance walked in six minutes (measured in metres) The result is compared to baseline values or population norms to assess improvements or declines in physical function. A greater distance walked indicates better physical function and endurance.

    Time frame: From enrollment to the end of treatment at 12 months

  9. Cognitive Function (MoCA)

    Cognitive function refers to participants' mental abilities, including memory, attention, reasoning, and problem-solving. This is often measured using cognitive screening tests or detailed neuropsychological assessments. Measuring Cognitive Function Cognitive Score: (Sum of individual test scores / Total possible score) × 100% Cognitive function is assessed using tools the Montreal Cognitive Assessment (MoCA). Lower scores may indicate cognitive impairment, while higher scores suggest better cognitive function.

    Time frame: From enrollment to the end of treatment at 12 months

  10. Residual Renal Function (Creatinine Clearance)

    Residual renal function refers to the remaining kidney function in patients who are on dialysis, often measured by creatinine clearance or urine output. Maintaining residual renal function is associated with better outcomes in dialysis patients. Measuring Residual Renal Function Residual Renal Function (Creatinine Clearance): Creatinine clearance (measured in mL/min) or urine output (measured in mL/day) Residual renal function is assessed through urine collections or serum creatinine measurements. Higher values suggest better kidney function, and changes are monitored to evaluate the need for adjustments in dialysis.

    Time frame: From enrollment to the end of treatment at 12 months

  11. Restless Legs Syndrome (IRLSSG)

    Restless legs syndrome (RLS) is a neurological condition characterised by an uncontrollable urge to move the legs, often due to uncomfortable sensations. It can significantly impact sleep and quality of life. Measuring Restless Legs Syndrome RLS Severity Score: (Sum of individual severity scores from scales like the International Restless Legs Syndrome Study Group (IRLSSG) rating scale / Total possible score) × 100% Higher scores indicate more severe symptoms, and the score is used to monitor the progression or improvement of RLS symptoms over time.

    Time frame: From enrollment to the end of treatment at 12 months

  12. >10g/L Rise in Haemoglobin (Hb)

    This refers to the increase in haemoglobin levels by more than 10g/L over a defined period, typically used as a marker for effective treatment of anemia in conditions like chronic kidney disease or during dialysis. Measuring \>10g/L Rise in Hb Rise in Hb Rate: (Number of participants with a \>10g/L rise in Hb / Total participants enrolled) × 100% This measures the proportion of participants who experience a significant increase in hemoglobin, indicating a positive response to treatment.

    Time frame: From enrollment to the end of treatment at 12 months

  13. % with Haemoglobin >110g/L

    This refers to the proportion of participants who achieve a haemoglobin level greater than 110g/L, often used as a target for managing anaemia in chronic conditions. Measuring % with Hb \>110g/L Hb \>110g/L Rate: (Number of participants with Hb \>110g/L / Total participants) × 100% This measure indicates the effectiveness of anaemia management and whether participants are reaching the desired target haemoglobin level.

    Time frame: From enrollment to the end of treatment at 12 months

  14. Ferritin >200ug/L

    Ferritin is a marker of iron stores in the body. A ferritin level greater than 200 ug/L is often used as a target in managing iron levels in patients with chronic kidney disease or anaemia. Measuring Ferritin Ferritin Rate: (Number of participants with ferritin \>200 ug/L / Total participants) × 100% A higher percentage indicates better iron repletion, while a lower rate suggests suboptimal iron stores, potentially requiring adjustment in treatment.

    Time frame: From enrollment to the end of treatment at 12 months

  15. TSAT >20%

    Transferrin saturation (TSAT) is a measure of iron availability for erythropoiesis. A TSAT greater than 20% is often a target in managing iron deficiency in patients, especially those on dialysis. Measuring TSAT TSAT \>20 Rate: (Number of participants with TSAT \>20% / Total participants) × 100% This rate indicates how many participants are achieving optimal iron saturation, which is crucial for effective anaemia management.

    Time frame: From enrollment to the end of treatment at 12 months

  16. % Receiving Rescue Therapy

    Rescue therapy refers to interventions given to patients who are not responding adequately to the initial treatment. In the context of anaemia management, this might involve additional iron infusions, blood transfusions, or an increase or initiation of erythropoiesis-stimulating agents (ESAs). Measuring % Receiving Rescue Therapy Rescue Therapy Rate: (Number of participants receiving rescue therapy / Total participants) × 100% A high rate of participants requiring rescue therapy could indicate that the initial treatment protocol is insufficient or needs adjustment.

    Time frame: From enrollment to the end of treatment at 12 months

  17. Quality-Adjusted Life Years

    Health economics involves evaluating the cost-effectiveness of interventions, considering the economic impact of treatment on the healthcare system, patient quality of life, and outcomes. Data will be collected on additional appointments and admissions. Measuring Health Economics Quality-Adjusted Life Years (QALYs): Often used to assess the benefit of a treatment by combining quality of life and survival data.

    Time frame: From enrollment to the end of treatment at 12 months

  18. Change in Erythropoiesis-Stimulating Agent (ESA) Dose

    This refers to the adjustment in the dose of erythropoiesis-stimulating agents (ESA), commonly used to treat anaemia by stimulating red blood cell production in patients with kidney disease. Measuring Change in ESA Dose Change in ESA Dose: (Difference in ESA dose before and after treatment) This can be measured as a percentage change from baseline, or as an increase/decrease in units per week. Adjustments are made based on the patient's haemoglobin response.

    Time frame: From enrollment to the end of treatment at 12 months

  19. Cumulative Iron Dose

    The cumulative iron dose refers to the total amount of iron administered over a period, typically used in the treatment of iron deficiency anaemia, especially in patients undergoing dialysis or with chronic kidney disease. Measuring Cumulative Iron Dose Cumulative Iron Dose: (Total amount of iron administered over a defined period) This is often tracked in milligrams or grams and can be used to assess the adequacy of iron supplementation and the need for future dosing adjustments. A higher cumulative dose may indicate greater iron deficiency or suboptimal absorption.

    Time frame: From enrollment to the end of treatment at 12 months

  20. Cost per Outcome

    Health economics involves evaluating the cost-effectiveness of interventions, considering the economic impact of treatment on the healthcare system, patient quality of life, and outcomes. Data will be collected on additional appointments and admissions. Measuring Health Economics Cost per Outcome: (Total cost of intervention / Total number of successful outcomes) This measure evaluates the economic efficiency of the intervention, with a lower cost per outcome indicating better value for the resources spent.

    Time frame: From enrollment to the end of treatment at 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Oct 2027, 23 months after the start.

Of 50 non-industry phase 3 interventional studies under Anemia, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 23 months is below that.

Counting every sponsor, half of 148 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Mar 19, 2025
StartActual
Nov 13, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06884280
Lead sponsor
Hull University Teaching Hospitals NHS Trust
Collaborators
Pharmacosmos Therapeutics, Inc.
Responsible party
Sponsor
First posted
Mar 19, 2025
Start date
Nov 13, 2025
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
May 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion